President Trump Emphasizes Drug Price Reduction at 2026 State of the Union
During the 2026 State of the Union address held on the evening of February 25th in Washington, President Trump dedicated a significant portion of his time to emphasizing his administration's efforts to reduce the cost of prescription drugs. He asserted that while many previous presidents were unable to address this issue, his administration had realized the goal of helping people access healthcare at a lower cost.
The President cited the “most-favored-nation” policy, a mechanism designed to bring drug prices in the United States to parity with those in other major Western countries. Simultaneously, he also introduced the TrumpRx platform, where pharmaceutical companies committed to providing many essential medicines at deeply discounted prices to American consumers.
According to the President's assertion, American citizens, who have borne the world's highest pharmaceutical prices for decades, will now begin to enjoy the most competitive prices. He stated that the advent of the TrumpRx system marked a major turning point, significantly easing the financial burden on families across the nation.
A Real Story from TrumpRx's First Customer
At the ceremony, the President invited Mrs. Catherine Rayner, the wife of a serviceman, to attend and introduced her as the first customer to use the TrumpRx platform. Mrs. Rayner's personal story was presented as a vivid testament to the practical effectiveness of the new healthcare policies being implemented by the administration.
Mrs. Rayner and her husband had faced difficulties conceiving and had to resort to in vitro fertilization (IVF). Previously, a necessary treatment medication cost up to $4,000, but after accessing the TrumpRx platform, she was able to purchase the same medication for just under $500.
Concluding his 1-hour-47-minute speech — the longest State of the Union in history — President Trump called on Congress to swiftly enact legislation to formalize the “most-favored-nation” policy. He emphasized that legislation is necessary to ensure the drug price reduction mechanism is sustainably maintained and not altered in the future.
